COVID-19 vaccine development from the perspective of cancer patients

References

• Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–37. doi:10.1016/S1470-2045(20)30096-6.
   PubMed Web of Science ®Google Scholar
• Dooling K, McClung N, Chamberland M, Marin M, Wallace M, Bell BP, Lee GM, Talbot HK, Romero JR, Oliver SE, et al. The Advisory Committee on Immunization Practices’ interim recommendation for allocating initial supplies of COVID-19 vaccine—United States, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1857–59. doi:10.15585/mmwr.mm6949e1.
   PubMed Web of Science ®Google Scholar
• International Agency for Research on Cancer. Global Cancer Observatory.
   Google Scholar
• Nabioullin R, Sone S, Mizuno K, Yano S, Nishioka Y, Haku T, Ogura T. Interleukin-10 is a potent inhibitor of tumor cytotoxicity by human monocytes and alveolar macrophages. J Leukoc Biol. 1994;55(4):437–42. doi:10.1002/jlb.55.4.437.
   PubMed Web of Science ®Google Scholar
• Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, Zhang Z, You H, Wu M, Zheng Q, et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783–91. doi:10.1158/2159-8290.CD-20-0422.
   PubMed Web of Science ®Google Scholar
• Rogado J, Pangua C, Serrano-Montero G, Obispo B, Marino AM, Perez-Perez M, Lopez-Alfonso A, Gullón P, Lara MÁ. COVID-19 and lung cancer: a greater fatality rate? Lung Cancer. 2020;146:19–22. doi:10.1016/j.lungcan.2020.05.034.
   PubMed Web of Science ®Google Scholar
• Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Disc. 2020;10(7):935–41. doi:10.1158/2159-8290.CD-20-0516.
   Web of Science ®Google Scholar
• Rubio MC, Sanchez L, Abreu-Ruíz G, Bermejo-Bencomo W, Crombet T, Lage A. COVID-19 and cancer in Cuba. Sem Oncol. 2020;47:328–29. doi:10.1053/j.seminoncol.2020.07.009.
   PubMed Web of Science ®Google Scholar
• Meng Y, Lu W, Guo E, Liu J, Yang B, Wu P, Lin S, Peng T, Fu Y, Li F, et al. Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis. J Hematol Oncol. 2020;13(1):75. doi:10.1186/s13045-020-00907-0.
   PubMed Web of Science ®Google Scholar
• Wang Q, Berger NA, Xu R. Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection. JAMA Oncol. 2020 Dec 10. doi:10.1001/jamaoncol.2019.5367.
   Web of Science ®Google Scholar
• Wang Q, Berger NA, Xu R. When hematologic malignancies meet COVID-19 in the United States: infections, death and disparities. Blood Rev. 2020;100775. doi:10.1016/j.blre.2020.100775.
   PubMed Web of Science ®Google Scholar
• Rüthrich MM, Giessen-Jung C, Borgmann S, Classen AY, Dolff S, Grüner B, Hanses F, Isberner N, Köhler P, Lanznaster J, et al. COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registry. Ann Hematol. 2021;100:383–93. doi:10.1007/s00277-020-04328-4.
   PubMed Web of Science ®Google Scholar
• Lunski MJ, Burton J, Tawagi K, Maslov D, Simenson V, Barr D, Yuan H, Johnson D, Matrana M, Cole J, et al. Multivariate mortality analyses in COVID‐19: comparing patients with cancer and patients without cancer in Louisiana. Cancer. 2020;127:266–74. doi:10.1002/cncr.33243.
   PubMed Web of Science ®Google Scholar
• Brar G, Pinheiro LC, Shusterman M, Swed B, Reshetnyak E, Soroka O. COVID-19 severity and outcomes in patients with cancer: a matched cohort study. JCO. 2020;38(33):3914–24. doi:10.1200/JCO.20.01580.
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Daffini R, Pagani C, Salvetti M, Mancini V, Borlenghi E, D’Adda M, Oberti M, Paini A, De Ciuceis C, et al. Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19. Cancer. 2020;126(23):5069–76. doi:10.1002/cncr.33160.
   PubMed Web of Science ®Google Scholar
• Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21(7):893–903. doi:10.1016/S1470-2045(20)30309-0.
   PubMed Web of Science ®Google Scholar
• Sng CCT, Wong YNS, Wu A, Ottaviani D, Chopra N, Galazi M, Benafif S, Soosaipillai G, Roylance R, Lee AJX, et al. Cancer history and systemic anti-cancer therapy independently predict COVID-19 mortality: a UK tertiary hospital experience. Front Oncol. 2020;10:595804. doi:10.3389/fonc.2020.595804.
   PubMed Web of Science ®Google Scholar
• Han HJ, Nwagwu C, Anyim O, Ekweremadu C, Kim S. COVID-19 and cancer: from basic mechanisms to vaccine development using nanotechnology. Int Immunopharmacol. 2021 Jan;90:107247. doi:10.1016/j.intimp.2020.107247.
   PubMed Web of Science ®Google Scholar
• Mercado NB, Zahn R, Wegmann F, Loos C, Chandrashekar A, Yu J, Liu J, Peter L, McMahan K, Tostanoski LH. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020;586(7830):583–88. doi:10.1038/s41586-020-2607-z.
   PubMed Web of Science ®Google Scholar
• Draft landscape of COVID-19 candidate vaccines. [accessed 2021 Jan 15]. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines .
   Google Scholar
• Brisse M, Vrba SM, Kirk N, Liang Y, Ly H. Emerging concepts and technologies in vaccine development. Front Immunol. 2020;11:583077. doi:10.3389/fimmu.2020.583077.
   PubMed Web of Science ®Google Scholar
• Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA vaccines for infectious diseases. Front Immunol. 2019;10:594. doi:10.3389/fimmu.2019.00594.
   PubMed Web of Science ®Google Scholar
• Wang Z, Troilo PJ, Wang X, Griffiths TG, Pacchione SJ, Barnum AB, Harper LB, Pauley CJ, Niu Z, Denisova L, et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther. 2004;11:711–21. doi:10.1038/sj.gt.3302213.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Pfizer-BioNTech COVID-19 Vaccine Emergency Use Authorization. Silver Spring (MD): US Department of Health and Human Services, Food and Drug Administration; 2020.
   Google Scholar
• Beyer WEP, Palache AM, de Jong JC, Osterhaus ADME. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine. 2002 Jan 31;20(9–10):1340–53. doi:10.1016/S0264-410X(01)00471-6.
   PubMed Web of Science ®Google Scholar
• Marian AJ. Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries. Cardiovasc Pathol. 2021 Jan-Feb;50:107278. doi:10.1016/j.carpath.2020.107278.
   PubMed Web of Science ®Google Scholar
• Brest P, Refae S, Mograbi B, Hofman P, Milano G. Host polymorphisms may impact SARS-CoV-2 infectivity. Trends Genet. 2020;36:813–15. doi:10.1016/j.tig.2020.08.003.
   PubMed Web of Science ®Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of aphase 1/2, single-blind, randomised controlled trial. Lancet (London, England). 2020;396:467–78. doi:10.1016/S0140-6736(20)31604-4.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States. https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html .
   Google Scholar
• Passwell J, Levanon M, Davidsohn J, Ramot B. Monocyte PGE2 secretion in Hodgkin’s disease and its relation to decreased cellular immunity. Clin Exp Immunol. 1983 Jan;51(1):61–68.
   PubMed Web of Science ®Google Scholar
• Poland GA. Influenza vaccine failure: failure to protect or failure to understand? Expert Rev Vaccines. 2018;17(6):495–502. doi:10.1080/14760584.2018.1484284.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, et al. An mRNA vaccine against SARS-CoV-2: preliminary report. N Engl J Med. 2020;383:1920–31. First data for the mRNA-1273 vaccine demonstrating safety, reactogenicity and immunogenicity of this platform in 18–55 year old adults.. doi:10.1056/NEJMoa2022483.
   PubMed Web of Science ®Google Scholar
• Vaccines and Related Biological Products Advisory Committee. Vaccines and Related Biological Products Advisory Committee December 10, 2020, meeting: sponsor briefing document. Silver Spring (MD): US Department of Health and Human Services, Food and Drug Administration; 2020.
   Google Scholar
• Hosoda T, Yokoyama A, Yoneda M, Yamamoto R, Ohashi K, Kagoo T, Ueno H, Boku S, Yano T. Bendamustine can severely impair T-cell immunity against cytomegalovirus. Leuk Lymphoma. 2013;54(6):1327–28. doi:10.3109/10428194.2012.739285.
   PubMed Web of Science ®Google Scholar
• Nakashima K, Aoshima M, Ohfuji S, Suzuki K, Katsurada M, Katsurada N, Misawa M, Otsuka Y, Kondo K, Hirota Y. Immunogenicity of trivalent influenza vaccine in patients with lung cancer undergoing anticancer chemotherapy. Hum VaccinImmunother. 2017;13(3):543–50. doi:10.1080/21645515.2016.1246094.
   Google Scholar
• Anderson H, Petrie K, Berrisford C, Charlett A, Thatcher N, Zambon M. Seroconversion after influenza vaccination in patients with lung cancer. Br J Cancer. 1999;80:219–20. doi:10.1038/sj.bjc.6690342.
   PubMed Web of Science ®Google Scholar
• Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:e44–e100.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Rollin L, Larkin J. Nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377:2503–04. doi:10.1056/NEJMoa1709684.
   PubMed Web of Science ®Google Scholar
• Postow MA, Hellmann MD. Adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:1165. doi:10.1056/NEJMra1703481.
   PubMed Web of Science ®Google Scholar
• Chong CR, Park VJ, Cohen B, Postow MA, Wolchok JD, Kamboj M. Safety of inactivated influenza vaccine in cancer patients receiving immune checkpoint inhibitors. Clin Infect Dis. 2020;70(2):193‐199. doi:10.1093/cid/ciz202.
   Web of Science ®Google Scholar
• Joona TB, Digkas E, Wennstig AK, Nyström K, Nearchou A, Nilsson C, Pauksens K, Valachis A. Influenza vaccination in breast cancer patients during subcutaneous trastuzumab in adjuvant setting. Breast Cancer Res Treat. 2020 Nov;184(1):45–52. doi:10.1007/s10549-020-05815-y.
   PubMed Web of Science ®Google Scholar
• Sodhi JS, Raja W, Zargar SA, Showkat A, Parveen S, Nisar S, Wani MA, Javid G, Khan M, Aejaz S, et al. The efficacy of accelerated, multiple, double-dose hepatitis B vaccine against hepatitis B virus infection in cancer patients receiving chemotherapy. Indian J Gastroenterol. 2015 Sep;34(5):372–79. doi:10.1007/s12664-015-0595-y.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu N-H, Nitsche A, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–80 e8. doi:10.1016/j.cell.2020.02.052.
   PubMed Web of Science ®Google Scholar
• Bitsor M, Galanakis E. Vaccine-preventable infection morbidity of patients with chronic kidney disease and cocoon vaccination strategies. Expert Rev Vaccines. 2015;14(10):1385–95. doi:10.1586/14760584.2015.1075397.
   PubMed Web of Science ®Google Scholar